

September 18, 2024

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---	---

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform you that the Company has entered into a binding agreement today, September 18, 2024, with GLS Pharma Limited, a subsidiary of the Company (GLS) and its promoters for acquisition of balance 5,90,361 equity shares of INR 10/- each (49% of GLS) for a purchase consideration of INR 22.5 crores. The shares are being acquired at a price of INR 381.12 per share. GLS will become a wholly owned subsidiary of the Company post the acquisition.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as '**Annexure A**'.

This is for your information and records.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: Annexure A

Annexure A

AUROBINDO PHARMA LIMITED
www.aurobindo.com

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 4023736370/23747340 Fax: +91 402374 1080/23746833
Email: info@aurobindo.com Website: www.aurobindo.com

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

<p>a) Name of the target entity, details in brief such as size, turnover etc.;</p>	<p>i) Name of the Target:</p> <p>GLS Pharma Limited</p> <p><u>Registered Office:</u> Galaxy, Floors 22-24, Plot No. 1, Survey No. 83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032.</p> <p>ii) Details of the Target:</p> <p>GLS Pharma Limited ("GLS") is a pharmaceutical company engaged in the business of Oncology products which include orals and injectables used in chemotherapy for solid malignancies, chemotherapy for hematological malignancies and chemo supportive products (the "Business").</p> <p>GLS was incorporated on 01/09/2004 and initiated manufacturing in the year 2015. It had a total sales of INR 32.99 crores during FY 23-24, INR 36.08 crores during FY 22-23 and INR 25.84 crores during FY 21-22.</p> <p>Aurobindo Pharma Limited (the "Company") is holding 51.00% in GLS. Mr. Suresh Pathak and his family members are holding 49.00% in GLS.</p> <p>The Company is acquiring the remaining 49% from Mr. Suresh Pathak and his family members.</p>
<p>b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length";</p>	<p>The proposed acquisition in GLS by the Company will not fall within the definition of related party transactions.</p>
<p>c) Industry to which the business of the target entity being acquired belongs;</p>	<p>Pharmaceutical industry and engaged in the business of Oncology products which include orals and injectables used in chemotherapy for solid malignancies, chemotherapy for hematological malignancies and chemo supportive products.</p>
<p>d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);</p>	<p>The Company had acquired 51% shares of GLS Pharma from Mr. Suresh Pathak and his family members, on June 17, 2022, and is now acquiring the balance 49% equity shares of GLS.</p> <p>This acquisition is undertaken to hold the entire ownership of GLS by the Company. GLS will become a wholly owned subsidiary of the Company post the acquisition.</p>

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500 038 T.S., INDIA Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com

e) Brief details of any governmental or regulatory approvals required for the acquisition.	No approval is required.
f) Indicative time period for completion of the acquisition.	The completion of the acquisition is estimated before December 31, 2024.
g) Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration of INR 22.5 crores.
h) Cost of acquisition and / or the price at which the shares are acquired;	The Company is purchasing 5,90,361 equity shares of INR 10/- each (49%) for a purchase consideration of INR 22.5 crores. The shares are being acquired at a price of INR 381.12 per share. The consideration shall be paid in cash.
i) Percentage of shareholding / control acquired and /or number of shares acquired;	The Company is acquiring 49% equity shares of GLS from Mr. Suresh Pathak and his family members. After completion of the transactions, the Company will hold 100% equity shares of GLS.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>GLS Pharma Limited is a pharmaceutical company engaged in the business of Oncology products which include orals and injectables used in chemotherapy for solid malignancies, chemotherapy for hematological malignancies and chemo supportive products.</p> <p>GLS was incorporated on 01/09/2004.</p> <p>It had a total sales of INR 32.99 crores during FY 23-24, INR 36.08 crores during FY 22-23 and INR 25.84 crores during FY 21-22.</p>

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500 038 T.S., INDIA Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com